NCT07076108View on ClinicalTrials.gov

Oral Vitamin C Administration on Erythropoietin Dosing Requirement in End-Stage Renal Disease Patients on Regular Hemodialysis

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 1, 2019

Primary Completion Date

December 1, 2024

Study Completion Date

December 1, 2024

Conditions
Vitamin COral AdministrationErythropoietinEnd-Stage Renal DiseaseRegular Hemodialysis
Interventions
DRUG

Normal regimen of treatment of anemia

Patients were on normal regimen of treatment of anemia.

DRUG

Vitamin C

Patients were on 250 mg oral vitamin C daily for 3 months.

DRUG

Vitamin C

Patients were on 500 mg oral vitamin C daily for 3 months.

Trial Locations (1)

11591

Ain Shams University, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER

NCT07076108 - Oral Vitamin C Administration on Erythropoietin Dosing Requirement in End-Stage Renal Disease Patients on Regular Hemodialysis | Biotech Hunter | Biotech Hunter